Carrier Screening Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 5.12 Billion |
| Market Size (2029) | USD 8.07 Billion |
| CAGR (2024 - 2029) | 9.53 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Carrier Screening Market Analysis
The Carrier Screening Market size is estimated at USD 5.12 billion in 2024, and is expected to reach USD 8.07 billion by 2029, growing at a CAGR of 9.53% during the forecast period (2024-2029).
COVID-19 had a significant impact on the growth of the market. The global carrier screening market faced limitations in development due to the sudden imposition of the worldwide lockdowns, which reduced the patient influx to genetic counselors. According to the study published in Prenatal Diagnosis in July 2021, the COVID-19 pandemic influenced pregnant women's decisions about prenatal genetic testing. Patients' access to and use of prenatal genetic tests impacted the pandemic. However, genetic testing for COVID-19 diagnosis increased during the pandemic. However, the relaxation of the restrictions during the post-pandemic period contributed to the market's growth. For instance, a study published in the European Journal of Human Genetics in November 2022 indicated that between 2020 and 2022, willingness to take a genetic test climbed considerably. Thus the market studied is expected to grow over the forecast period.
The significant factors for the growth of the carrier screening market include the increasing emphasis on early disease detection and prevention and the rising application of screening tests in genetic disorders, which is expected to experience during the forecast period. For instance, the Centers for Disease Control and Prevention (CDC) data updated in May 2022 reported that sickle cell disease affects millions of people throughout the world and is particularly common among those ancestors who came from sub-Saharan Africa, Spanish-speaking regions, such as South America, the Caribbean, and Central America, as well as Saudi Arabia, India, and Mediterranean countries.
Additionally, the rising demand for personalized medicine and various activities taken by market players are expected to boost the market growth. For instance, in May 2021, AdventHealth expanded its genomics program with the launch of a data-driven precision medicine initiative that would structure and integrate longitudinal patient data with molecular testing data, creating a dataset and disease network models to help the health system better predict the development of diseases and responses to treatments. Moreover, increased product launches by the market players are expected to support the market expansion. For instance, in June 2021, Grail launched the Galleri blood test, a groundbreaking multi-cancer screening diagnostic. The test was meant to screen people who may already have an elevated risk for cancer, such as adults over the age of 50 years.
Thus, all the factors above, such as the rising prevalence of genetic diseases and the increasing adoption of precision medicine, are expected to boost the market over the forecast period. However, the social and ethical implications and the high costs and reimbursement issues of carrier testing are restraining the market's growth.
Carrier Screening Market Trends
This section covers the major market trends shaping the Carrier Screening Market according to our research experts:
Molecular Screening Test Segment is Expected to Register Significant Growth during the Forecast Period
A molecular screening test identifies DNA mutations, which are variations in the genetic code that lead to decreased production of enzymes. It focuses on the mutations seen in one ethnic group. It involves a stepwise testing process for common alleles and, if required, extensive gene analysis. Sequencing is a method of molecular screening accomplished by reading across the DNA code of a specific gene to know if there are any known mutations. If the test results are negative, it reduces the chances that the individual is a carrier. However, it does not eliminate the possibility of having a carrier gene since the mutation might still need to be discovered through the current technology.
According to the Minority of HIV/AIDS Fund (MHAF), United States Department of Health and Human Services Statistics, updated in June 2021, estimated that approximately 37.6 million people were living with HIV worldwide in 2020, of whom 35.9 million were adults and 1.7 million were children (under the age of 15). According to the same source, 1.5 million people were estimated to have contracted HIV globally in 2020. The market is expanding due to the rising prevalence of HIV and the resulting demand for carrier screening. The increasing need for screening tests results from the high prevalence of viral illnesses.
Furthermore, globally, there is an increasing cancer incidence, driving the market growth. For instance, according to Cancer Facts and Figures 2022, published in January 2022 by the American Cancer Society, an estimated 1.9 million new cancer cases would be diagnosed in 2022, among which prostate cancer is estimated to be 186,670, followed by 169,870 cases of lung cancer, and 144,490 cases of female breast cancer. Therefore, the global incidence of cancer and modern healthcare facilities have been major drivers of the segment's growth.
There is an expansion of molecular testing, as it has the potential to increase testing accuracy through technical benefits for many targeted disorders that may not be suggested for biochemical testing. Thus, the abovementioned factors are expected to drive market growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America holds a major share of the carrier screening market and is expected to show a similar trend over the forecast period without significant fluctuations.
According to statistics published by the Government of Canada and released in November 2021, about 229,200 Canadians were diagnosed with cancer in 2021. Prostate cancer was expected to remain the most diagnosed cancer, accounting for 46% of all cancer diagnoses in 2021. According to the same source, breast cancer affected one out of every eight women at some point. Thus, the growing prevalence of cancer is expected to increase demand for carrier screening, thereby boosting market growth.
The increasing product approvals by the US Food and Drug Administration (FDA) and subsequent launches, along with the high concentration of key players involved in research activities for the innovation of novel genetic testing products, are anticipated to drive market growth in North America. For instance, in January 2022, Mitera announced the release of its Peaches & Me and 23Pears at-home reproductive genetic testing kits in all 50 states. Peaches & Me is the first non-invasive prenatal test (NIPT) that patients can order online and have administered at home. As early as ten weeks of pregnancy, it can screen for disorders like Down syndrome and determine the baby's gender.
Thus, considering the above factors, such as the rising prevalence of cancer and product launches, is expected to fuel market growth in the North American region over the forecast period.
Carrier Screening Industry Overview
The Carrier Screening Market is fragmented and competitive and consists of several major players. In terms of market share, a few major players dominate the market. The presence of major market players, such as Abbott, F. Hoffmann-La Roche AG, Danaher Corporation (Cepheid), Illumina Inc., and Thermo Fisher Scientific Inc, is increasing the overall competitive rivalry of the market.
Carrier Screening Market Leaders
Illumina Inc.
Thermo Fisher Scientific Inc.
Abbott Laboratories
F.Hoffmann-La Roche Ltd
Danaher Corporation ( Cepheid)
*Disclaimer: Major Players sorted in no particular order
Carrier Screening Market News
- December 2022- Oxford Nanopore Technologies and Bio-Techne formed a strategic partnership to develop an integrated wet- and dry-lab kit for genotyping 11 genes essential for carrier screening.
- March 202- BillionToOne raised USD 125 million in the Series C funding co-led by Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others.
Carrier Screening Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Rising Demand for Personalized Medicine
4.2.3 Increasing Application of Screening Tests in Genetic Disorders
4.3 Market Restraints
4.3.1 Social and Ethical Implications of Carrier Screening
4.3.2 High Costs and Reimbursement Issues of Carrier Testing
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD Million)
5.1 By Test Type
5.1.1 Molecular Screening Test
5.1.2 Biochemical Screening Test
5.2 By Disease Type
5.2.1 Cystic Fibrosis
5.2.2 Tay-Sachs
5.2.3 Gaucher Disease
5.2.4 Sickle Cell Disease
5.2.5 Spinal Muscular Atrophy
5.2.6 Other Autosomal Recessive Genetic Disorders
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 23Andme Inc.
6.1.2 Abbott Laboratories
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Cepheid (Danaher Corporation)
6.1.5 Illumina Inc.
6.1.6 Luminex Corporation
6.1.7 Sequenom Inc. (Laboratory Corporation of America Holdings)
6.1.8 Myriad Genetics
6.1.9 Autogenomics Inc.
6.1.10 Thermo Fisher Scientific Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Carrier Screening Industry Segmentation
Carrier screening is a type of genetic test to identify autosomal recessive genetic disorders before or during a pregnancy stage. Further, it helps in identifying a child with a genetic disorder.
The Carrier Screening Market is Segmented by Test Type (Molecular Screening Test and Biochemical Screening Test), Disease Type (Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell Disease, Spinal Muscular Atrophy, and Other Autosomal Recessive Genetic Disorder), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.
| By Test Type | |
| Molecular Screening Test | |
| Biochemical Screening Test |
| By Disease Type | |
| Cystic Fibrosis | |
| Tay-Sachs | |
| Gaucher Disease | |
| Sickle Cell Disease | |
| Spinal Muscular Atrophy | |
| Other Autosomal Recessive Genetic Disorders |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Carrier Screening Market Research FAQs
How big is the Carrier Screening Market?
The Carrier Screening Market size is expected to reach USD 5.12 billion in 2024 and grow at a CAGR of 9.53% to reach USD 8.07 billion by 2029.
What is the current Carrier Screening Market size?
In 2024, the Carrier Screening Market size is expected to reach USD 5.12 billion.
Who are the key players in Carrier Screening Market?
Illumina Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, F.Hoffmann-La Roche Ltd and Danaher Corporation ( Cepheid) are the major companies operating in the Carrier Screening Market.
Which is the fastest growing region in Carrier Screening Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Carrier Screening Market?
In 2024, the North America accounts for the largest market share in Carrier Screening Market.
What years does this Carrier Screening Market cover, and what was the market size in 2023?
In 2023, the Carrier Screening Market size was estimated at USD 4.67 billion. The report covers the Carrier Screening Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Carrier Screening Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Carrier Screening Industry Report
Statistics for the 2023 Carrier Screening market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Carrier Screening analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
